BriaCell Therapeutics Corp. (TSE:BCT – Get Free Report) shares traded down 0.8% during mid-day trading on Wednesday . The company traded as low as C$4.74 and last traded at C$4.74. Approximately 131 shares were traded during mid-day trading, a decline of 99% from the average session volume of 17,928 shares. The stock had previously closed at C$4.78.
BriaCell Therapeutics Stock Performance
The company has a market capitalization of C$41.24 million, a PE ratio of -5.64 and a beta of 1.96. The company has a 50 day moving average price of C$4.70 and a 200 day moving average price of C$5.25.
About BriaCell Therapeutics
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX:BCT) is dedicated to developing novel immunotherapies to fight cancer and improve patients’ lives. Immunotherapies have become the forefront of the fight against cancer because they use the body’s immune system to destroy cancer cells, offer the potential for higher levels of safety and efficacy than chemotherapy, and may also prevent cancer recurrence.
Featured Stories
- Five stocks we like better than BriaCell Therapeutics
- GE Vernova’s AI Power Boom Faces a Profit Test
- Cardinal Health Earnings: Can Perfection Get Priced In Twice?
- Nebius’ Q2 Beat Shows the AI Bottleneck Is Capacity, Not Demand
- Legacy Jet Builders Stall While Embraer Accelerates to New Highs
Receive News & Ratings for BriaCell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BriaCell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
